A:

Biotech giant Amgen Inc (AMGN) bills itself as one of the first biotechnology firms. It was founded in 1980 and has grown into a firm with 20,000 employees, a market capitalization of nearly $100 billion, and approximately $20 billion in annual sales. Below is an overview of its main rivals.

Product Rivals

Any pharmaceutical or biotech firm is technically a rival to Amgen, though there is a smaller subset of rivals that sell similar drugs to Amgen. For instance, Johnson & Johnson (JNJ) sells Procrit, which is a competitor to Aranesp and Amgen’s stable of anemia treatments. Teva Pharmaceutical (TEVA) also sells an increasing array of biosimilar drugs to Aranesp  Amgen’s Enbrel helps treat arthritis, which competes with AbbVie’s (ABBV) popular Humira drug. Celgene (CELG) sells Revlimid to treat myeloma and Amgen is in the process of getting into the field with the acquisition of Onyx and its Kyprolis drug, also for the treatment of myeloma.      

Biotech Competition

In general, Amgen competes with other large biotech firms. Biogen Idec (BIIB) sells a number of drugs to help treat multiple sclerosis and is seeing success with the launch of a couple of drugs to treat hemophilia. Celgene sells drugs that help treat cancer and immune-inflammatory diseases. Gilead Sciences (GILD) offers a number of drugs that help patients suffering from HIV and recently released Solvadi, which has had great success in helping patients with hepatitis C infections.

The Bottom Line

A number of firms continue to muscle into Amgen’s core businesses of treating anemia, arthritis, and myeloma. Generic versions will also continue to be introduced as Amgen’s drug patents expire over time. Most investment bankers and analysts, however, still project Amgen will remain profitable over time. 

At the time of writing, Ryan C. Fuhrmann is long shares of Amgen and Gilead but did not own shares in any of the other companies mentioned in this article.

RELATED FAQS
  1. Who are Gilead Sciences' (GILD) main competitors?

    Learn about the pharmaceutical company Gilead Sciences and its main competitors. Explore the company's role in creating HIV-preventing ... Read Answer >>
  2. How does government regulation impact the drugs sector?

    Government regulation lengthens the process for bringing new pharmaceuticals to market and restricts the drugs sector to ... Read Answer >>
  3. Do financial advisors get drug tested?

    Financial advisor regulatory bodies do not require drug testing, but many individual firms that hire advisors do. Read Answer >>
  4. Can your insurance company drug test you?

    Learn why insurance companies conduct drug tests and how a lifestyle free of drugs can save you big money on health and life ... Read Answer >>
  5. How does operating leverage affect business risk?

    Learn how operating leverage affects business risk and how companies measure it. Review a relevant example of operating leverage ... Read Answer >>
Related Articles
  1. Investing

    AMGN: How Amgen's Stock Price Rose 18.55% in 6 Months

    Amgen's stock price has outpaced biotechnology and health care ETFs over the past six months due to a solid product pipeline and rapidly increasing dividends.
  2. Investing

    Analyzing Amgen's Price & Profitability Ratios in 2016 (AMGN)

    Learn about Amgen's price ratios and profitability ratios and discover why it has one of the highest profit margins in the global pharmaceutical sector.
  3. Insights

    Amgen’s Kyprolis Fails in Trial (AMGN)

    The failure in a comparative study has raised doubts about Amgen’s $10.4 billion takeover of the drug.
  4. Investing

    How Amgen Makes Billions On Just A Few Drugs

    Amgen produces relatively few drugs, but that's doesn't mean it's any less essential or profitable. Here's a look at the $120B company.
  5. Investing

    Biotech Stocks Are Suddenly a Bargain

    The huge drop in biotech stocks has turned many into bargains, including Amgen, Biogen and others.
  6. Investing

    Amgen's Dividend Could Double in 5 Years (AMGN)

    Amgen's (NASDAQ: AMGN) dividend yield of 1.9% may not look very enticing to investors looking for income today. But a close look at Amgen stock reveals that where the biotechnology company lacks ...
  7. Investing

    Amgen, Janssen to Begin Myeloma Trial (AMGN, JNJ)

    The companies will launch combination drug studies to treat multiple myeloma, or cancer of the plasma cells.
  8. Investing

    Judge Lifts Ban on Amgen Cholesterol Drug Rival

    A judge temporarily allowed Regeneron to keep its rival of Amgen's cholesterol drug on the market.
  9. Investing

    Amgen Expands New Drugs Into Indian Market (AMGN, RDY)

    The company is building on its existing alliance with Dr. Reddy’s Laboratories for marketing three new drugs in India.
  10. Investing

    Why Amgen's Stock May Rise Over 30%: Todd Gordon

    Amgen shares could surge 30% in 2018.
RELATED TERMS
  1. Blockbuster Drug

    A blockbuster drug is an extremely popular drug that generates ...
  2. Healthcare Sector

    The healthcare sector consists of companies that provide medical ...
  3. Abbreviated New Drug Application (ANDA)

    Abbreviated New Drug Application (ANDA) is a written request ...
  4. Phase 4

    Phase 4 refers to the final stage of new drug testing, which ...
  5. Side Effect

    Side effect is a negative or undesirable symptom or condition ...
  6. Orphan Drug Credit

    The orphan drug credit helps pharmaceutical companies absorb ...
Trading Center